Brief: China Resources Pharmaceutical Says Tasly Pharmaceutical Posts HY Net Profit Attributable Of RMB 892.7 MLN
21/08/2026 16:45
BRIEF-China Resources Pharmaceutical Says Tasly Pharmaceutical Posts HY Net Profit Attributable Of RMB 892.7 MLN Aug 21 (Reuters) - China Resources Pharmaceutical Group Ltd 3320.HK:
H1 2026 NET PROFIT ATTRIBUTABLE FOR TASLY PHARMACEUTICAL RMB 892.7 MILLION
H1 2026 REVENUE DOWN 2.03% TO RMB 4.20 BILLION FOR TASLY PHARMACEUTICAL
Further company coverage: 3320.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on China Resources Pharmaceutical
See all newsBrief: China Resources Pharmaceutical Group Declares Interim Dividend Of RMB0.087 Per Share
Brief: China Resources Pharmaceutical Says Tasly Pharmaceutical Posts HY Net Profit Attributable Of RMB 892.7 MLN
Brief: China Resources Pharmaceutical Group Says HY Revenue RMB 1.93 Billion For CR Jiangzhong
Brief: China Resources Pharmaceutical Group Posts HY Revenue RMB 1.64 Billion, Down 50.97% For KPC Pharmaceuticals
Brief: China Resources Pharmaceutical Says CR Boya Bio-Pharmaceutical Posts Quarterly Unaudited Revenue RMB 321.1 Million, Net Profit RMB 30.0 Million